Provided by Tiger Trade Technology Pte. Ltd.

Carisma Therapeutics, Inc.

0.0457
+0.006516.58%
Volume:48.69K
Turnover:2.02K
Market Cap:1.91M
PE:0.24
High:0.0459
Open:0.0459
Low:0.0389
Close:0.0392
52wk High:1.27
52wk Low:0.0307
Shares:41.85M
Float Shares:31.26M
Volume Ratio:0.36
T/O Rate:0.16%
Dividend:- -
Dividend Rate:- -
EPS(TTM):0.1920
EPS(LYR):-1.4588
ROE:-362.79%
ROA:33.03%
PB:-2.21
PE(LYR):-0.03

Loading ...

Carisma Therapeutics Delists Common Stock

Reuters
·
Dec 29, 2025

Carisma Therapeutics to Voluntarily Delist from Nasdaq December 25

Reuters
·
Dec 06, 2025

Carisma Announces Delisting From Nasdaq and SEC Deregistration

THOMSON REUTERS
·
Dec 06, 2025

Carisma Therapeutics Inc expected to post a loss of 12 cents a share - Earnings Preview

Reuters
·
Nov 03, 2025

Kepler Capital Reaffirms Their Buy Rating on Carmila SAS (CARM)

TIPRANKS
·
Oct 26, 2025

BRIEF-Carisma Therapeutics - CEO Steven Kelly To Leave Effective Nov 15 - SEC Filing

Reuters
·
Oct 16, 2025

Carisma Therapeutics - to Appoint Consultant to Serve as CEO & Manage Remaining Wind-Down Activities

THOMSON REUTERS
·
Oct 16, 2025

Carisma Therapeutics - as Part of Wind Down Activities, CEO Steven Kelly to Leave Effective Nov 15 - SEC Filing

THOMSON REUTERS
·
Oct 16, 2025

Carisma Therapeutics Announces Separation Agreements with CEO and CSO, Detailing Severance and Pro-Rated Bonuses Amid Wind Down

Reuters
·
Oct 16, 2025

BUZZ-U.S. STOCKS ON THE MOVE-Venture Global, TSMC, Oracle

Reuters
·
Oct 11, 2025

Carisma Therapeutics Faces Nasdaq Delisting and Trading Suspension

TIPRANKS
·
Oct 10, 2025

Carisma Therapeutics to Be Delisted from Nasdaq Will Trade on OTCID Amid Regulatory Noncompliance

Reuters
·
Oct 10, 2025

Top Executive Sells Thousands of Carisma Therapeutics Shares!

TIPRANKS
·
Oct 09, 2025

Carisma Therapeutics Chief Scientific Officer Michael Klichinsky Reports Disposal of Common Shares

Reuters
·
Oct 09, 2025

Carisma Therapeutics Insider Makes a Significant Stock Sale!

TIPRANKS
·
Oct 04, 2025

Carisma Therapeutics Chief Scientific Officer Michael Klichinsky Reports Disposal of Common Shares

Reuters
·
Oct 04, 2025

Ocugen Faces Merger Termination with Carisma Therapeutics

TIPRANKS
·
Sep 18, 2025

Carisma Therapeutics Amends Agreement with Moderna

TIPRANKS
·
Sep 18, 2025

Carisma Therapeutics Inc - Co & Modernatx Amend Collaboration & and License Agreement - SEC Filing

THOMSON REUTERS
·
Sep 18, 2025

Carisma Therapeutics - Modernatx to Pay $4 Mln to Co & Has No Further Obligation to Make Any Financial Payments - SEC Filing

THOMSON REUTERS
·
Sep 18, 2025